Daniel Malarek, Chief Executive Officer of Foundation Medicine, shared on LinkedIn:
“We are proud to celebrate the five companion diagnostic indication approvals we secured in the first half of 2026 across our tissue- and liquid-based comprehensive genomic profiling tests. These approvals span across different cancers, including to help identify patients with METex14 skipping alterations in NSCLC, HRR gene-mutated mCRPC, PIK3CA-mutated HR+/HER2- breast cancer, and ALK fusion gene-positive solid tumors who may be eligible for targeted treatments.
Thank you to everyone at Foundation Medicine for your dedication and collaboration in driving these innovations forward. These new approvals build upon our legacy of developing high-quality diagnostic tests to identify the genomic mutations driving a patient’s tumor and match a patient to the most effective treatment options.
Read more about the critical role of companion diagnostics in patient care.”
Other articles about Foundation Medicine on OncoDaily.